Shares of Aspen Aerogels, Inc. (NYSE:ASPN - Get Free Report) have been assigned a consensus rating of "Buy" from the ten ratings firms that are covering the stock, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $28.70.
ASPN has been the topic of a number of research reports. Roth Mkm reduced their target price on shares of Aspen Aerogels from $36.00 to $31.00 and set a "buy" rating on the stock in a report on Friday, November 8th. Benchmark restated a "buy" rating and issued a $14.00 price objective on shares of Aspen Aerogels in a report on Thursday, August 8th. Barclays lowered their target price on Aspen Aerogels from $27.00 to $25.00 and set an "overweight" rating for the company in a research report on Tuesday, November 12th. HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of Aspen Aerogels in a research report on Wednesday, October 16th. Finally, TD Cowen raised their price objective on Aspen Aerogels from $36.00 to $41.00 and gave the stock a "buy" rating in a research report on Tuesday, August 20th.
Read Our Latest Analysis on ASPN
Insider Activity
In other news, CEO Donald R. Young sold 63,355 shares of the stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $30.03, for a total transaction of $1,902,550.65. Following the transaction, the chief executive officer now owns 483,640 shares of the company's stock, valued at $14,523,709.20. This represents a 11.58 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.30% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Aspen Aerogels
A number of institutional investors have recently modified their holdings of the company. Franklin Resources Inc. increased its holdings in Aspen Aerogels by 5.3% during the 3rd quarter. Franklin Resources Inc. now owns 29,418 shares of the construction company's stock worth $815,000 after purchasing an additional 1,483 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Aspen Aerogels during the third quarter worth $498,000. Geode Capital Management LLC raised its position in Aspen Aerogels by 5.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,385,968 shares of the construction company's stock valued at $38,385,000 after buying an additional 75,024 shares during the last quarter. Barclays PLC lifted its stake in Aspen Aerogels by 333.8% during the 3rd quarter. Barclays PLC now owns 92,302 shares of the construction company's stock valued at $2,557,000 after acquiring an additional 71,024 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in Aspen Aerogels during the 3rd quarter worth $420,000. 97.64% of the stock is owned by institutional investors and hedge funds.
Aspen Aerogels Trading Up 2.2 %
Shares of ASPN stock traded up $0.32 during mid-day trading on Friday, reaching $14.80. 1,050,117 shares of the stock traded hands, compared to its average volume of 2,921,014. The company has a market cap of $1.21 billion, a price-to-earnings ratio of 1,481.48 and a beta of 2.21. The company has a quick ratio of 2.48, a current ratio of 2.93 and a debt-to-equity ratio of 0.27. The stock's fifty day simple moving average is $19.94 and its two-hundred day simple moving average is $23.91. Aspen Aerogels has a 1-year low of $10.31 and a 1-year high of $33.15.
About Aspen Aerogels
(
Get Free ReportAspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.
See Also

Before you consider Aspen Aerogels, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aspen Aerogels wasn't on the list.
While Aspen Aerogels currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.